We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





New Biochip Array Developed for ApoE4 Classification

By LabMedica International staff writers
Posted on 04 Aug 2016
Print article
Image: The semi-automated benchtop Evidence Investigator analyzer (Photo courtesy of Randox).
Image: The semi-automated benchtop Evidence Investigator analyzer (Photo courtesy of Randox).
Apolipoprotein E (APOE) plays a key role in lipid metabolism and is recognized as one of the most powerful genetic risk factors for dementia and other neurodegenerative diseases. It has become one of the most widely studied gene variants in Alzheimer’s disease and constitutes a major consideration for preventive medicine.

Biochip Array Technology (BAT) enables the determination of multiple analytes from a single sample. This technology has been successfully applied to a new biochip array to directly identify from a plasma sample whether patients are ApoE4 heterozygous, homozygous or null through simultaneous detection of both total ApoE levels and specific ApoE4 levels.

Scientists at Randox Teoranta (Dungloe, Ireland) and their colleagues studied an initial cohort of 272 plasma samples of known genotype, which were used to establish initial assay parameters. ApoE exists in three common isoforms (ApoE2, ApoE3 and ApoE4), which are coded by three co-dominant alleles (e2, e3, e4). As such six common ApoE phenotypes exist within the general population E2/E2, E3/E3, E4/E4 (homozygous) and E2/E3, E2/E4, E3/E4 (heterozygous). A further cohort of 112 plasma samples of unknown genotype was utilized to verify performance characteristics established employing the initial cohort.

The team used a simultaneous chemiluminescent biochip-based sandwich immunoassays for measurement of ApoE4 and total ApoE directly from plasma samples were employed and applied to the Evidence Investigator analyzer (Randox Laboratories, Crumlin, UK; www.randox.com). Genotype concordance was further investigated by genotyping these same 112 plasma samples from circulating cell free DNA (cfDNA) through the use of another biochip array platform, based on a combination of multiplex polymerase chain reaction (PCR) and biochip array hybridization, which allows simultaneous detection of APOE specific single nucleotide polymorphisms (SNPs).

The scientists reported that from the initial cohort of 272 samples with known genotypes, 100% were correctly identified as null, heterozygous or homozygous for ApoE4 by the biochip array. From the additional 112 plasma samples, analyzed using BAT for protein and SNPs detection, 100% concordance was found between both approaches. ROC analysis showed that patient samples could be identified as APOE4 positive or negative with 100% sensitivity and 100% specificity, all in approximately three hours.

The investigators concluded that BAT can be successfully applied to provide a platform to rapidly and accurately detect an individual’s APOE4 status directly from a plasma sample. In combination with medical and family history, medication and lifestyle, this can deliver valuable information for personalized medicine approaches. An individual’s APOE status has been shown to affect pre-symptomatic risk, diagnosis, prognosis, and treatment response for a variety of diseases, in particular Alzheimer’s disease. The study was presented at the 68th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting held July 31 to August 4, 2016, in Philadelphia, PA, USA.

Related Links:
Randox
American Association of Clinical Chemistry
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.